Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: The VALERIA trial

Jan Menne, Csaba Farsang, László Deák, Sven Klebs, Matthias Meier, Renate Handrock, Christian Sieder, Hermann Haller

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objectives: Microalbuminuria is known as an independent predictor for stroke, myocardial infarction, and death. The purpose of the VALERIA trial was a comparison of the efficacy and safety of combination therapy of valsartan and lisinopril with valsartan and lisinopril high-dose monotherapy in patients with hypertension and microalbuminuria. Methods: This was a randomized, double-blind, interventional, parallel-group study. After a washout/placebo- run-in phase of 3 weeks, 133 patients were randomized to treatment (1: 1:1) with either lisinopril 40 mg, valsartan 320 mg, or a combination of valsartan/lisinopril 320/20 mg for 30 weeks. Results: At baseline, the urine albumin creatinine ratio was similar for the three treatment groups (geometric means, lisinopril 9.6 mg/mmol, valsartan 9.1 mg/mmol, and valsartan/lisinopril 9.5 mg/mmol). After 30 weeks of treatment, the geometric mean urine albumin creatinine ratio had decreased in all three groups by 41, 51, and 62% to 5.7 mg/mmol (lisinopril), 4.5 mg/mmol (valsartan), and 3.6 mg/mmol (valsartan/lisinopril). The decrease for valsartan/lisinopril was statistically significantly greater compared with lisinopril [adjusted ratio 60%, confidence interval (38-94%), P = 0.029]. Normalization of microalbuminuria was greatest with valsartan and valsartan/lisinopril (lisinopril 17%, valsartan 31%, and valsartan/lisinopril 38% of patients) and was statistically significant for lisinopril in contrast with valsartan/lisinopril (P = 0.034). Differences in blood pressure reduction between the groups were not statistically significant. All treatments were safe and well tolerated. Conclusion: The combination of valsartan and lisinopril provided a significantly better reduction of urine albumin creatinine ratio and more than doubled the rate of patients with normalized urine albumin creatinine ratio compared with lisinopril alone. All treatments were safe and well tolerated.

Original languageEnglish
Pages (from-to)1860-1867
Number of pages8
JournalJournal of hypertension
Volume26
Issue number9
DOIs
Publication statusPublished - Sep 2008

Keywords

  • Combination therapy
  • Hypertension
  • Lisinopril
  • Microalbuminuria
  • Urinary albumin creatinine ratio
  • Urinary albumin excretion
  • Valsartan

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: The VALERIA trial'. Together they form a unique fingerprint.

  • Cite this